Latest News Archives

Content Team In Clinical Publications, Latest News

Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment

Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary…

Content Team In Finances, Latest News

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule…

Content Team In Finances, Latest News

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market

Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m…

Content Team In Clinical Trials, Latest News

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency…

Content Team In Clinical Trials, Latest News

Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial

Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate…

Content Team In Finances, Latest News

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP)…

Content Team In Latest News

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology

Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement EINDHOVEN, The Netherlands, 11…

Content Team In Clinical Trials, Latest News

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2…

Content Team In Clinical Trials, Latest News

Xeltis announces FDA Breakthrough Device Designation for aXess™ and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages…

Content Team In Latest News

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership…